WEHI spinout aims to revolutionize the development of cancer drugs - News-Medical

Summary

The article discusses the launch of Ternarx, a WEHI spinout biotech company in Australia. It focuses on developing targeted therapies for hard-to-treat cancers, including neuroblastoma, using innovative protein degrader technology. Key figures like Michelle Haber and substantial funding from MRFF highlight its potential impact on cancer treatment.